Australia markets closed

Akero Therapeutics, Inc. (AKRO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.92-0.81 (-3.91%)
At close: 04:00PM EDT
19.92 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.38B
Enterprise value 510.02M
Trailing P/E 8.18
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.63
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) -0.29
52-week change 3-56.37%
S&P500 52-week change 326.49%
52-week high 358.38
52-week low 311.25
50-day moving average 322.86
200-day moving average 327.08

Share statistics

Avg vol (3-month) 31.24M
Avg vol (10-day) 3559.04k
Shares outstanding 569.15M
Implied shares outstanding 670.24M
Float 854.76M
% held by insiders 15.44%
% held by institutions 1105.91%
Shares short (30 Apr 2024) 48.6M
Short ratio (30 Apr 2024) 412.22
Short % of float (30 Apr 2024) 412.81%
Short % of shares outstanding (30 Apr 2024) 412.44%
Shares short (prior month 28 Mar 2024) 47.84M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-20.23%
Return on equity (ttm)-31.11%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -204.05M
Net income avi to common (ttm)-179.27M
Diluted EPS (ttm)-3.24
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)903.67M
Total cash per share (mrq)13.07
Total debt (mrq)35.82M
Total debt/equity (mrq)4.23%
Current ratio (mrq)30.12
Book value per share (mrq)12.24

Cash flow statement

Operating cash flow (ttm)-155.88M
Levered free cash flow (ttm)-94.74M